Who are Bilastine 0.6%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bepreve, Levocetirizine (drug), olopatadine 0.2% ophthalmic solution, bepotastine besilate ophthalmic solution, Cetirizine Dry Syrup, Xarlin (Levocetirizine).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bilastine-0-6.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bilastine 0.6% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bilastine 0.6% (Bilastine 0.6%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist. Area: Allergy.

phase 2 H1-receptor antagonist H1-receptor Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Bilastine 0.6% (Bilastine 0.6%) — Faes Farma, S.A.. Bilastine is an antihistamine that works by blocking the action of histamine, a substance in the body that causes allergy symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bilastine 0.6% TARGET	Bilastine 0.6%	Faes Farma, S.A.	phase 2	H1-receptor antagonist	H1-receptor
Bepreve	BEPOTASTINE	Bausch Health	marketed	Histamine-1 Receptor Antagonist	H1-receptor, mast cells	2009-01-01
Levocetirizine (drug)	Levocetirizine (drug)	UCB Pharma	marketed	H1-receptor antagonist (second-generation antihistamine)	H1-receptor
olopatadine 0.2% ophthalmic solution	olopatadine 0.2% ophthalmic solution	Allergan	marketed	H1-receptor antagonist	H1-receptor
bepotastine besilate ophthalmic solution	bepotastine besilate ophthalmic solution	Bausch & Lomb Incorporated	marketed		H1-receptor, mast cells
Cetirizine Dry Syrup	Cetirizine Dry Syrup	GlaxoSmithKline	phase 3	H1-receptor antagonist (second-generation antihistamine)	H1-receptor
Xarlin (Levocetirizine)	Xarlin (Levocetirizine)	HK inno.N Corporation	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist class)

Allergan · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Faes Farma, S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bilastine 0.6% — Competitive Intelligence Brief. https://druglandscape.com/ci/bilastine-0-6. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing